On April 12, 2021, the Food and Drug Admin-istration (FDA) temporarily lifted its decades-long restriction on access to medication abortion, which accounts for two in five abortions in the United States.1 The agency’s action nullifies a Supreme Court order, 3 months earlier in Food and Drug Administration v. American Col-lege of Obstetricians and Gynecologists(FDA v. ACOG), requiring that pa-tients prescribed the abortion pill mifepristone pick it up in person, even during the pandemic. Al-though the direct ruling in FDA v. ACOG is now moot, we believe that its stealth logic still has troubling implications beyond medical care and public health.